We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.9B
AUM Growth
+$737M
Cap. Flow
-$219M
Cap. Flow %
-1.29%
Top 10 Hldgs %
56.42%
Holding
122
New
26
Increased
36
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$353M
2
EQIX icon
Equinix
EQIX
+$266M
3
BKNG icon
Booking.com
BKNG
+$252M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$203M
5
AABA
Altaba Inc
AABA
+$162M

Top Sells

Rank Stock Value
1
KDP icon
Keurig Dr Pepper
KDP
+$596M
2
XL
XL Group Ltd.
XL
+$407M
3
LOGM
LogMein, Inc.
LOGM
+$214M
4
GILD icon
Gilead Sciences
GILD
+$207M
5
IQV icon
IQVIA
IQV
+$126M

Sector Composition

Rank Sector Weight
1 Healthcare 24.15%
2 Technology 17.4%
3 Communication Services 12.66%
4 Financials 12.19%
5 Industrials 5.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
76
DELISTED
ChemoCentryx, Inc.
CCXI
$14.5M 0.09%
1,150,000
– –
SLDB icon
77
Solid Biosciences
SLDB
$839M
$13.9M 0.08%
+19,667
New +$12.4M
ORBK
78
DELISTED
Orbotech Ltd
ORBK
$13.7M 0.08%
+230,000
New +$14.4M
DVAX
79
DELISTED
Dynavax Technologies
DVAX
$13.3M 0.08%
1,070,000
-370,000
-26% -$5.01M
BLCM
80
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$13.2M 0.08%
213,663
+13,663
+7% +$925K
CHRS icon
81
Coherus Oncology
CHRS
$202M
$11.6M 0.07%
700,000
-145,000
-17% -$2.57M
ASMB icon
82
Assembly Biosciences
ASMB
$531M
$11.1M 0.07%
+25,000
New +$11.7M
BMS
83
DELISTED
Bemis
BMS
$10M 0.06%
206,660
-235,840
-53% -$11.1M
VOYA icon
84
Voya Financial
VOYA
$9.29B
$9.19M 0.05%
185,000
– –
FATE icon
85
Fate Therapeutics
FATE
$323M
$8.63M 0.05%
+530,000
New +$6.27M
ECYT
86
DELISTED
Endocyte, Inc. Common Stock
ECYT
$7.1M 0.04%
+400,000
New +$6.87M
ITCI
87
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.42M 0.03%
+250,000
New +$5.23M
TBIO
88
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.5M 0.03%
450,000
+50,000
+13% +$582K
KALV
89
DELISTED
KalVista Pharmaceuticals
KALV
$4.42M 0.03%
+200,000
New +$2.7M
SPPI
90
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$4.2M 0.02%
250,000
+200,000
+400% +$4.33M
CRNX icon
91
Crinetics Pharmaceuticals
CRNX
$8.9B
$4.06M 0.02%
+141,815
New +$4.21M
GCVRZ
92
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.82M 0.02%
6,827,805
– –
PRNB
93
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$3.65M 0.02%
+125,000
New +$3.53M
YMAB
94
DELISTED
Y-mAbs Therapeutics
YMAB
$3.32M 0.02%
+125,000
New +$3.18M
PFNX
95
DELISTED
Pfenex Inc.
PFNX
$3.07M 0.02%
600,000
– –
ARQL
96
DELISTED
Arqule Inc
ARQL
$2.83M 0.02%
+500,000
New +$2.84M
VTAK icon
97
Catheter Precision
VTAK
$980K
$2.73M 0.02%
+1
New +$4.54M
STRO icon
98
Sutro Biopharma
STRO
$420M
$2.25M 0.01%
+15,000
New +$2.27M
TYME
99
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$1.13M 0.01%
405,857
-542,533
-57% -$1.41M
AKRX
100
DELISTED
Akorn Inc
AKRX
$909K 0.01%
70,000
-370,000
-84% -$6.08M
1 2 3
4
5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Farallon Capital Management held 122 positions worth $16.9B, up 4.6% from $16.2B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Farallon Capital Management's Q3 2018 filing shows 26 new, 36 increased, 29 reduced and 20 closed positions. Its largest new stake was Equinix: 608,600 shares worth $263M. The largest sale was Keurig Dr Pepper, an estimated $596M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Communication Services.

  • Farallon Capital Management's largest Q3 2018 buy was Equinix: 608,600 shares worth $263M.
  • Farallon Capital Management added most to Express Scripts Holding Company in Q3 2018, an estimated $353M increase.
  • Farallon Capital Management's biggest Q3 2018 reduction was IQVIA, cutting an estimated $126M.
  • Farallon Capital Management fully exited Keurig Dr Pepper in Q3 2018, selling an estimated $596M.
  • Farallon Capital Management's ten largest holdings make up 56% of its $16.9B portfolio in Q3 2018.
  • Farallon Capital Management opened 26 new positions and closed 20 in Q3 2018.
  • Farallon Capital Management's portfolio value rose 4.6% quarter-over-quarter to $16.9B.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.